PhosImmune, Inc. is a cancer immunnotherapy company which was founded to commercialize a library of phosphopeptide tumor targets (PTTs) discovered at the University of Virginia (UVa) and the University of Birmingham (UK). PhosImmune has developed a proprietary PTT screening methodology which allows for rapid identification and selection of PTTs for therapeutic applications.

Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations.